Forbes October 10, 2023
Abbott Laboratories wearables with a biosensor are performing well with consumers in the United Kingdom, a test market that precedes an eventual U.S. regulatory filing later this year for these devices known as “biowearables,” the company’s CEO said Tuesday.
Abbott, which already has a top-selling continuous glucose monitor for diabetes management known as Libre that generates more than $4 billion in sales annually, is developing a new line of biowearables known as Lingo that tracks glucose levels, ketones and lactate.
This new category of consumer biowearables, which attach beneath the skin to give more precise and accurate data about what is going on in someone’s body, is the latest evolution in medical devices for Abbott. The healthcare company is already...
Today's Sponsors
Today's Sponsor